A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Trial Profile

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 104
  • Sponsors Gilead Sciences; Japan Tobacco
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 May 2017 Results of a pooled analysis (n=1733) from NCT01780506 and NCT01797445 studies assessing efficacy and safety in older HIV infected treatment naive adults over 96 weeks, presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society.
    • 09 Mar 2017 Results of pooled analysis (n=1733) of week 144 data from two studies (NCT01780506 and NCT01797445) published in the JAIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top